Mometason Cipla (Mometasone Furoate)

Mometasone furoate, the active ingredient in Mometason, is a corticosteroid presented as a nasal spray for nasal use. It treats allergic rhinitis and nasal polyps in adults and children as prescribed.

GNH USA supplies Mometason as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mometason (mometasone furoate) is a topical corticosteroid used to manage inflammatory conditions of the nasal passages.

Allergic rhinitis: reduces nasal congestion, sneezing, itching and rhinorrhea. Nasal polyps: decreases polyp size and improves nasal airflow.

Mometason may cause local and systemic adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nasal irritation or burning sensation - Headache - Epistaxis (nosebleed) - Altered taste or bitter aftertaste - Throat irritation or dryness - Cough

Serious or Rare Side Effects: - Nasal septal perforation - Severe allergic reaction (anaphylaxis) - Vision changes such as blurred vision - Adrenal suppression with prolonged high‑dose use - Opportunistic fungal infection of the nasal mucosa

Before using Mometason, consider the following safety measures.

Hypersensitivity: avoid if known allergy to mometasone furoate or other corticosteroids. Recent nasal surgery or trauma: use only under medical supervision. Long‑term use: monitor for nasal bleeding or mucosal thinning. Children: follow prescriber guidance on dosing frequency. Concurrent intranasal decongestants: limit duration to reduce risk of rebound congestion. Store at room temperature: keep in the original container, protect from moisture and heat.

Mometason can interact with other medicines that affect corticosteroid activity or metabolism.

Major Interactions (Avoid): - Systemic corticosteroids: increased risk of systemic glucocorticoid effects. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise local exposure. - Live vaccines: potential reduction in vaccine efficacy.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin): may modestly increase exposure. - Antifungal azoles (e.g., fluconazole): monitor for local irritation.